Oricell Therapeutics - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeOricell Therapeutics
Oricell Therapeutics logo

Oricell Therapeutics

0 followers

About Oricell Therapeutics

Oricell Therapeutics is a biotechnology company focused on cancer immunotherapy, developing innovative cell therapies and antibody platforms. It operates with a global development approach, leveraging proprietary technologies to advance therapies for solid and hematologic malignancies, with activities centered in China and international collaborations. The company highlights its OriAb and OriCAR platforms, CAR-T programs such as OriCAR-017 and Ori-C101, and CMC capabilities to support clinical development and manufacturing. Its pipeline targets unmet clinical needs in cancers like multiple myeloma, liver cancer, and other solid tumors.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

Rick Xu

Chief Medical Officer

Helen Yang

Co-founder/Chairperson/CEO

Peter He

Co-founder & CSO

Iris Huang

Chief Financial Officer

Key Facts

HQ Location

China

Founded

2015

Employees

11 - 50

Status

Private

Website

https://oricell.com